Introduction
Cell cycle transition through mitosis requires the timely destruction of regulatory molecules such as securin and cyclin B (Harper et al., 2002; Peters, 2002) . This highly orchestrated process is accomplished by ubiquitin activating (E1), conjugating (E2) and ligating (E3) proteins, which covalently attach ubiquitin to substrates, thereby targeting them for degradation by the 26S proteasome (Mayer, 2000) . Securin and cyclin B ubiquitination appears to require the E2 conjugating enzyme UbcH10 (UBEC2) and E3 ligase proteins contained within a large multi-subunit complex, termed the anaphase-promoting complex/cyclosome (APC/C). Consistent with these data, mutation of the active site cysteine of UbcH10 confers a dominant-negative phenotype that results in metaphase arrest, demonstrating that this protein is essential for cell cycle progression (Townsley et al., 1997) .
Although clearly associated with regulation of the cell cycle, the potential role of UbcH10 in cancer development has only recently been explored. Expression of the mouse ortholog of human UbcH10, mEC-2, was reportedly upregulated in NIH3T3 cells transformed by EWS/FLI1, activated cdc42, v-ABL or c-myc, but not in a nontransformed NIH3T3 clone expressing EWS/ FLI1 (Arvand et al., 1998) . Although not specifically highlighted in expression profiling studies, the levels of UbcH10 transcript have also been identified as highly elevated in different types of cancers, such as ovarian (Welsh et al., 2001b) and metastatic prostatic adenocarcinomas (LaTulippe et al., 2002) . A recent comparison of expression levels of 17 E2 ubiquitin ligase genes in normal and tumor tissues identified UbcH10 as most specifically associated with cancer, and consistent with this notion overexpression of UbcH10 in NIH3T3 cells led to an increased proliferative capacity (Okamoto et al., 2003) . Although provocative, many of these observations can be explained on the basis of the cell cycle-dependent expression of UbcH10 regulated by the APC/C (Yamanaka et al., 2000) . A specific oncogenic role for UbcH10 has yet to be established.
Here, we used gene expression profiling to identify genes whose expression is highly elevated in carcinomas of diverse anatomic origins. An analysis of transcript levels in 151 cancers and 35 normal corresponding tissues identified expression of UbcH10 as most significantly elevated in tumors of multiple sites. We show that overexpression of UbcH10 in some carcinomas may be due, at least in part, to genomic amplification of the UbcH10 locus. We also show that selective silencing of UbcH10 by RNA interference (RNAi), in combination with TRAIL/DR5 agonistic antibodies, resulted in enhanced cell death in neoplastic but not nonmalignant human cells.
Results

UbcH10 is overexpressed in carcinomas of diverse anatomic origin
We compared the levels of expression of 12 535 transcripts in 151 carcinomas of the prostate, colon, lung, breast, kidney, liver, ovary, pancreas, gastro-esophagus and bladder, against those in 35 normal counterpart tissues (Su et al., 2002; Welsh et al., 2003) to search for genes whose expression was highly elevated in cancer. Genes were ranked based on the significance of the difference (unpaired t-test) and fold change between their expression levels in tumor versus normal tissues. The most highly ranked gene in this analysis (Table 1) , was the E2 ubiquitin conjugase, UbcH10, which was significantly overexpressed in a wide variety of carcinomas (Figure 1a) . Overall, the fold change among cancers of all sites (as compared to normal tissues) was 11.4 (P ¼ 3.37 Â 10 À18 by Student's t-test; Table 1 ). The difference in transcript levels between carcinomas with the most striking overexpression was 70-, 47-, 19-and 12-fold in tumors of the gastro-esophagus, lung, breast and ovary, respectively.
In silico validation of UbcH10 overexpression and association with tumor grade
We validated UbcH10 overexpression in two ways. First, we interrogated UbcH10 expression in the ONCOMINE database (Rhodes et al., 2004) , which ), bladder (grade 2 versus grade 3, P ¼ 0.02) and brain (glioblastoma; grade 1 versus grade 4, P ¼ 0.002) (Figure 1b) . Based on this information, we also evaluated UbcH10 expression as a function of grade in a series of 36 stage III/IV ovarian carcinomas (unpublished data). Expression of the gene in grade 3 carcinomas (n ¼ 16) was 1.8-and 4.7-fold greater than in grade 2 (n ¼ 15) and grade 1 (n ¼ 5) differentiated carcinomas, respectively, consistent with a recent report demonstrating significant overexpression of UbcH10, among other genes, in grade 3 versus grade 1 ovarian carcinomas (Jazaeri et al., 2003) . Together, these data confirm UbcH10 overexpression in a diverse array of human cancers, and strongly support an association between high UbcH10 gene expression and poor tumor differentiation.
Overexpression of the UbcH10 protein is correlated with gene expression and associated with mitosis
We next generated a monoclonal antibody against recombinant UbcH10 protein and used it to examine protein expression by immunohistochemistry on two tissue microarrays containing 389 tissue cores: 196 from normal human tissues and 229 from carcinomas representing the same anatomic sites as in our transcript databases. Expression of the UbcH10 protein was largely consistent with measurements of UbcH10 transcription in carcinomas, where overexpression of UbcH10 in tumors was typically characteristic of those with rapidly dividing cells (e.g. lung, ovarian, colorectal and gastric adenocarcinomas), whereas localized, lowstage tumors, such as the prostate carcinomas in our collection (Welsh et al., 2001a) , typically did not exhibit highly elevated levels of the transcript or protein (Figure 2a ). Expression of UbcH10 was clearly associated with cell division, as intense staining by IHC was seen in cells undergoing mitosis (e.g. Figure 2b ), and in normal cells present in the proliferative compartment of tissues (e.g. lymphocytes of lymphoid germinal centers, basal cells of the esophagus, colonic crypt and gastric neck epithelium). These data were consistent with measurements of the transcript in the GNF BodyAtlas (www.gnf.org; version 2), which identified lymphoid tissues (tonsil, thymus, bone marrow) as among the tissues with highest expression (data not shown).
The UbcH10 locus at 20q13.1 is amplified in gastroesophageal carcinomas
Although an association with cell cycle was clearly demonstrated by the analysis of UbcH10 gene and protein expression, we noted that the extent of UbcH10 overexpression in some tumors far exceeded that of other cell cycle-regulated genes that are typically associated with the fraction of cells in G2/M phase (e.g. cdc2, cdc20; Figure 3a , highlighted by arrows), suggesting that expression of the gene may not simply reflect rapid growth rates, but rather tumor-specific deregulation. The UbcH10 gene is localized to 20q13.1, a chromosomal region frequently associated with genomic amplification in many types of cancers, including those for which we had observed particularly high levels of UbcH10 expression. Using comparative genomic hybridization (CGH), one of us (WE-D) previously showed that amplification of 20q is the most frequent genetic aberration in upper gastrointestinal carcinomas (El-Rifai et al., 2001) . A re-evaluation of these data showed that subregional 20q amplification in most tumors encompassed 20q13.1 (Figure 3b ). To further evaluate whether UbcH10 was a 'target' of these amplifications, we performed real-time PCR (RT-PCR), CGH and quantitative DNA PCR (qPCR) to measure the levels of gene expression, chromosomal and locus-specific copy number, respectively, in an independent series of 20 gastric adenocarcinomas (Figure 3c ). Overexpression of UbcH10 (42-fold) was observed in 17/20 cases, four of which had 420-fold increases in expression. By CGH, 16/20 tumors showed amplification at 20q, encompassing all of the cases with 420-fold overexpression. Locus-specific amplification using PCR primers specific for the UbcH10 gene also identified increases in UbcH10 copy number in 13/20 cases, again including the cases with high-level amplification.
Reduction of cell growth by RNAi-mediated silencing of UbcH10 expression
To investigate the consequences of gene silencing in tumor cells with high UbcH10 levels, we designed sequences for three independent, nonoverlapping small interfering RNAs (siRNAs) (UbcH10-495, UbcH10-378, UbcH10-412; see Materials and methods). Each siRNAs was initially tested in two cell lines that were technically amenable to high-efficiency siRNA transfection: T3M4, derived from a human pancreatic carcinoma, and DLD-1, derived from a human colorectal adenocarcinoma, which we used for all of the experiments described below. All three of the siRNAs targeted to UbcH10, but not control siRNA, resulted in efficient diminution of the UbcH10 protein (Figure 4a ), which correlated with their ability to suppress cell growth (Figure 4b ). We also tested UbcH10-495 (hereafter referred to as siUbcH10) to evaluate UbcH10 knockdown in other cancer-derived cells, such as HeLa (cervical), Igrov-1 (ovarian), HCT15 (colon) and HCT116 (colon), all of which express high levels of the UbcH10 transcript and protein. Successful knockdown was observed in each cell type resulting in growth arrest (data not shown). Transfection of normal human fibroblasts (BJ) and mammary epithelial cells (HMECs) also resulted in successful knockdown of the protein; however, the extent of growth arrest in these cells was not as dramatic, perhaps because of the slower relative levels of growth of these cells (KW Wagner, LM Sapinoso and GM Hampton, unpublished data). As a further test of their specificity, we also examined the levels of cyclin B1 by Western blot analysis following UbcH10 silencing, based on the observation that the Figure 3 Genomic amplification of UbcH10 in gastro-esophageal carcinomas. (a) Upregulation of UbcH10 exceeds that of other cell cycle-associated genes. The relative hybridization intensity (X-axis) of the UbcH10, cdc2 and cdc20 genes is shown for a series of 15 gastric carcinomas. The arrowheads highlight those tumors (e.g. G3, G5, G9, etc.) with significant overexpression of UbcH10, which contrasts with other tumors (e.g. G18, G296, X58, etc.) with comparable levels of expression of all three genes. (b) CGH profile of 20q13.1 in human gastric cancers. An ideogram of chromosome 20 is shown to the left of the figure, highlighting the location of UbcH10 at 20q13.1. Black bars represent increased copy number (denoted by the intensity of the bar) in individual gastric carcinoma xenografts. Tumors showed different extents of amplification, involving the entire chromosome, the long arm of the chromosome or subregions, all of which encompass 20q13.1. In total, 15/20 tumors showed amplification at 20q, encompassing all of the cases with 420-fold overexpression. (c) DNA amplification at the UbcH10 locus. RT-PCR and qPCR were used to measure levels of UbcH10 expression, chromosomal and gene copy number in the same series of 20 xenografted gastric adenocarcinomas (X-axis). Greater than twofold overexpression (fold change versus normal tissue, Y-axis) of UbcH10 was observed in 17/20 cases (black bars), four of which had 420-fold increases in expression. By PCR with primers specific for the UbcH10 locus, we also identified increases in UbcH10 copy number in 13/20 cases (yellow bars). Cases with gross chromosomal amplification detected by CGH (GCH þ ) are ordered on the left-hand side of the graph; cases without gross abnormalities (CGHÀ) are depicted on the right-hand side of the graph UbcH10-APC complex controls cyclin B1 degradation. Our results revealed an inverse correlation between the levels of UbcH10 protein in cells treated with siUbcH10 and the levels of cyclin B1 (Figure 4a) . Overall, these data underscore the specificity of the UbcH10 siRNAs and indicate that the results are not due to 'off-target' effects. Finally, cell cycle analysis by FACS following siUbcH10 treatment showed arrest in G2/M phase consistent with previous reports (Townsley et al., 1997) . Microscopically, downregulation of UbcH10 did not induce any changes in cell morphology indicative of apoptosis, such as cell rounding, detachment, nuclear condensation or production of apoptotic bodies. Moreover, siUbcH10 treatment did not result in proteolytic processing of the two executioner caspases, caspase-3 and -7 (Salvesen and Dixit, 1997), as measured by Western blot analysis (Figure 4a ).
Downregulation of UbcH10 sensitizes cells to TRAIL/ DR5-mediated cell killing
Since most current chemotherapeutic drugs do not exhibit cancer cell specificity, and thus suffer from a low therapeutic index, novel approaches currently focus on the development of transformation-and tumorspecific inhibitors, such as EGFR antagonists (Grunwald and Hidalgo, 2003) (Boye et al., 2003) and TRAIL agonists (LeBlanc and Ashkenazi, 2003) . Although suppression of cell proliferation by targeting UbcH10 may have therapeutic potential (viz-a-viz small molecule inhibitors), such inhibition would be cytostatic and not necessarily tumor-specific. Therefore, we sought to combine UbcH10 silencing with cancer-specific apoptosis-inducing agents to determine if this combination might provide an enhanced benefit.
Since T3M4 and DLD-1 cells both express the TRAIL/DR5 receptor (data not shown), we focused our attention on a functionally agonistic antibody capable of triggering DR5/TRAIL-mediated apoptosis. This antibody, DR5-A, specifically recognizes and induces caspase-dependent cell death through the TRAIL/DR5 receptor and not other members of the tumor necrosis family of receptors (see Materials), such as DR4 or the TRAIL decoy receptors DcR1 and DcR2 (LeBlanc and Ashkenazi, 2003) . Incubation of either cell line with the DR5-A antibody for 6 h subsequent to exposure of the cells with a control siRNA (FITCconjugated siRNA) resulted in essentially no difference in cell viability compared to cells that were not exposed to antibody as determined by cell counting (Table 2) . However, when DR5-A was applied to cells for 6 h subsequent to treatment with siUbcH10, we observed a significant enhancement of apoptosis (41 and 28% relative decrease in T3M4 and DLD-1 cell viability, respectively; Table 2 ). We confirmed that the reduction in cell number was a consequence of caspase activation using a standard fluorescent caspase activity assay on cell lysates at 4 h ( Figure 5 ). From these data, caspase-3/ 7 activation was increased B2-fold in both cell lines compared to cells transfected with control siRNA and treated with DR5-A. In contrast to the induction of cell death in cancer cells, we did not see any evidence for sensitization of primary human skin fibroblasts (BJ) or HMECs to DR5-A subsequent to UbcH10 silencing Figure 4 Silencing the UbcH10 gene by RNAi. (a) Efficacy of UbcH10 siRNAs. At 48 h after siRNA transfection, total cell lysates were prepared and normalized for protein concentration. As shown by Western blot analysis, all three siRNAs tested induced downregulation of UbcH10 at the protein level in T3M4 and DLD-1 cancer cell lines. UbcH10 silencing raised the levels of cyclin B1, but did not activate one of the two main executioner caspases, caspase-3 or -7. Expression of b-actin was used to control equal protein loading (40 mg). (b) Growth rates after siUbcH10 treatment. The two cancer cell lines T3M4 (upper graph) and DLD-1 (lower graph) were transfected with different siUbcH10s and the relative member of viable cells was determined by MTT assay. SiRNA duplexes against Luciferase GL3 were used as a control. Absorbances were read at 570 nm and the data are the mean of triplicates (Figure 6 ), even though the growth of these cells was slightly affected by siUbcH10 over time.
Discussion
We identified UbcH10 as one of the most highly expressed genes in common human carcinomas relative to corresponding normal tissues. This observation, which we validated with a novel UbcH10-specific monoclonal antibody, is consistent with a recent report by Okamoto et al. (2003) , who compared the expression of 17 Ub-E2 genes in a small series of tumor and normal tissues, concluding that UbcH10 expression was cancerassociated. Although clearly coupled to the cell cycle in physiologically normal cells, we noted that the extent of UbcH10 overexpression in some tumors far exceeded that of other cell cycle-associated genes, and this observation, together with its genomic location at 20q13.1, led us to identify a high degree of locus-specific amplification in gastric/esophageal adenocarcinomas, consistent with a high percentage of overexpression in these tumors. This may reflect a general phenomenon in human cancers, as 20q amplification is common among diverse carcinomas. Although the correlation between genomic (CGH) amplification and gene expression was not completely concordant, the trend between genomic aberration and amplification was clear, and we attribute at least some of the discrepancies to the generally lower resolution of CGH. Primer-specific DNA qPCR also demonstrated copy number increases at the UbcH10 locus, further supporting amplification of this gene at the DNA level. Again, the correlation of expression and amplification was not perfect, underscoring the fact that other mechanisms leading to deregulation of UbcH10 must be operative in cancer cells. It is important to note that our data do not rule out the possibility that other genes are the targets of 20q amplification in these tumors, and that even with locus-specific primers our results could be interpreted as co-amplification of a closely adjacent gene(s). Indeed, amplification of other genes at 20q is very likely to contribute to these malignancies, as several genes previously reported as amplified in this region are known to exert oncogenic effects in partially transformed cells (Cuthill et al., 1999; Watanabe et al., 2002) . Experiments to evaluate other candidate oncogenes residing at the 20q locus by siRNA-mediated gene silencing are currently under way. Nevertheless, our data suggest that selection of increased UbcH10 expression plays an oncogenic role in many types of carcinoma, which is consistent with the observation that overexpression of UbcH10 in NIH3T3 cells leads to increased colony formation in soft agar assays (Okamoto et al., 2003) .
To evaluate the contribution of increased UbcH10 expression in cancer cells, we used gene silencing by siRNA transfection (Borkhardt, 2002) , which resulted in reduced viability of all of the tumor cell lines as well as (Table 2) correlates with the induction of caspase-3/7 using a fluorogenic DVED substrate. Cells were processed as described in Materials and methods and the cleavage of the DVED substrate (represented by V max on the X-axis) was measured in triplicate cell lysates following exposure of transfected cells (with control siRNA (siCon) or siUbcH10 (siUbc)) with control antibody or DR5-A several nontransformed primary cell lines that we tested. However, we did not observe any evidence of apoptosis, indicating that cells undergo cell cycle arrest rather than cell death -an observation supported by our own cell cycle analysis as well as experiments employing a dominant-negative UbcH10 mutant (Townsley et al., 1997) . Although blocking tumor cell proliferation by targeting UbcH10 alone may provide a therapeutic benefit (e.g. by using UbcH10-selective small molecules), we evaluated whether UbcH10 silencing in combination with other agents would provide an enhanced therapeutic potential. We reasoned that the combination of 'standard-of-care' chemotherapeutics (e.g. mitotic inhibitors, DNA intercalating agents and so forth) would not provide additional benefit, since they do not necessarily exhibit tumor cell-specific action. Thus, we focused our attention on antibodies (DR5-A) capable of eliciting tumor cell-specific apoptosis via the TRAIL/DR5 receptor. Although both of the tumor cell lines that we tested are sensitive to some extent to TRAIL-induced cell death, we observed a significant enhancement of apoptosis using a combination of siUbcH10 and DR5-A. Importantly, we observed no induction of cell death in nontransformed cells, even in the presence of siUbcH10. We have also tested one TRAIL-resistant tumor cell line (the androgen-independent xenograft-derived CWR-RV1) and found that it was not sensitized to TRAIL by downregulation of UbcH10. Thus, it appears that only tumors with at least some sensitivity to TRAIL/DR5-induced cell death might benefit from the combination of UbcH10 inhibition and TRAIL agonists.
Several studies have recently shown that chemical induction of cell cycle arrest in G1 sensitizes tumors cells to TRAIL-mediated cell death. Simvastatin/lovostatin (Jin et al., 2002), resveratrol (Fulda and Debatin, 2004) and pioglitazone (Goke et al., 2001 ) arrest tumor cells in G1 through the induction of p21/WAF-1/CIP-1. Administration of TRAIL to pretreated cells leads to dramatic enhancement of cell death. In the case of resveratrol, p21 induction is accompanied by the reduction of the inhibitor of apoptosis (IAP), survivin, which may be causal in sensitizing cells to TRAIL (Fulda and Debatin, 2004) . A more comprehensive analysis of TRAIL sensitivity at G0/G1 (by serum starvation), S (using aphidicolin) and G2/M (using nocodazole) demonstrated that tumor cell death is enhanced predominantly in the G0/G1 phase (Jin et al., 2002) . In contrast, roscovitine, a cdc2/cdk2 inhibitor, shifts glioma cells toward a G2/M arrest and sensitizes cells to TRAIL-mediated cell death, in line with the results presented here. Treatment with roscovitine results in the downregulation of survivin (perhaps via p21 induction); however, XIAP, which is the most potent IAP (Deveraux and Reed, 1999) , is also downregulated, in contrast to cells treated with the G0/G1 agent, resveratrol, in which XIAP levels were unchanged. Although it is tempting to speculate that the TRAIL sensitivity mediated by UbcH10 blockage may also be mediated by p21 induction and survivin/XIAP downregulation, this needs to be tested. It is also plausible that a rate-limiting component of the TRAIL pathway is a direct target of the ubiquitin-conjugating function of UbcH10 leading to its stabilization.
In summary, we show that UbcH10 is highly overexpressed in carcinomas of diverse anatomic origin. Its expression is also associated with the degree of tumor differentiation in several distinct types of human cancer. Mechanistically, overexpression of UbcH10 is mediated, at least in part, by genomic amplification, suggesting an increased requirement and selection Figure 6 Enhanced apoptosis of siUbcH10/DR5-treated tumor cells. (a) Primary human fibroblasts (BJ), HMECs, T3M4 and DLD-1 cells sequentially treated with siUbcH10 (siUbcH10-495) for 48 h followed by agonistic DR5-A antibodies (1 mg/ml) for an additional 6 h. Cells were analysed by bright-field contrast microscopy ( Â 10 magnification). Incubation with the DR5-A antibody following siUbcH10 silencing exhibited enhanced cell death in tumor cells (T) T3M4 and DLD-1 cells (arrowheads), but not in normal BJ or HMEC cells (N) during tumorigenesis. Finally, the use of TRAIL pathway agonists subsequent to UbcH10 inhibition may yield a greater therapeutic index than that currently obtained with standard chemotherapeutic drugs.
Materials and methods
Materials
Cell culture reagents were purchased from Gibco (Invitrogen/ Gibco, Carlsbad, CA, USA); all other chemicals were from Sigma Aldrich (St Louis, MO, USA). Tumor and corresponding normal tissue samples were obtained from the University of Virginia Health Sciences Center, and processed as described (Su et al., 2002; Welsh et al., 2003) . Cell lines CWR-RV1 and BJ were purchased from the ATCC (Rockville, MD, USA) and HMECs were purchased from Clonetics (Walkersville, MD, USA). T3M4 cells are a kind gift of Andreas Marti and Hans Graber (University of Bern, Switzerland). The DR5-specific agonist antibody was isolated from a functional screen for DR5 receptor-mediated cell killing (M Nasoff and D Knee, unpublished). The monoclonal antibody against UbcH10 was generated and tested using standard procedures.
Microarray hybridization and data analysis
Microarray hybridizations were performed and analysed as described previously (Su et al., 2002; Welsh et al., 2003) .
Quantitative RT-PCR
For quantitative RT-PCR, 47 primary gastric/esophageal adenocarcinomas and 13 normal gastric epithelial samples were collected, and verified by histologic examination (HF Frierson Jr, a board-certified pathologist). Tumors ranged from well-differentiated (WD) to poorly differentiated (PD), stages I-IIIa, and included both intestinal and diffuse-type tumors. mRNA was isolated using the RNeasy kit (QIAGEN Gmbh, Hilden, Germany). Single-stranded cDNA was synthesized using the Advantaget RT-for-PCR Kit (Clontech, Palo Alto, CA, USA). DNA was available from 20 of the same tumors. qPCR was performed in triplicate using iCycler (BioRad, Hercules, CA, USA). Gene-specific primers for UbcH10 and b-actin (control gene) were designed for both cDNA and DNA evaluations. Fold mRNA overexpression or DNA amplification was calculated according to the formula 2 (RtÀEt) / 2 (RnÀEn) as described previously (El-Rifai et al., 2001) , where Rt is the threshold cycle number for the reference gene in the tumor, Et for the experimental gene in the tumor, Rn for the reference gene in the normal sample and En for the experimental gene in the normal sample. The primers used for UbcH10 amplification are as follows: UbcH10 DNA sense primer, 5 0 -AGGCTAGGCATAGTGGCTCA-3 0 ; UbcH10 DNA antisense primer, 5 0 -TGTTGAGCTGGTTCTGATGC-3 0 ; UbcH10 cDNA sense primer, 5 0 -GGATTTCTGCCTTCC CTGAA-3 0 ; UbcH10 cDNA antisense primer, 5 0 -GATAGCA GGGCGTGAGGAAC-3 0 .
siRNA design and transfection protocol siRNAs against UbcH10 were designed via three independent selection programs from Dharmacon (Lafayette, CO, USA), Ambion (Austin, TX, USA) and an in-house algorithm at GNF (termed 'siRNA Picker') using published standard criteria. The selected sequences were: siUbcH10-495, cDNA position 495-513: 5 0 -AA-CCUGCAAGAAACCUACUCAdTdT-3 0 ; siUbcH10-378, cDNA position 378-396: 5 0 -AA-UGAUGUCAGGACCAUUCUG-dTdT-3 0 ; siUbcH10-412, cDNA position 412-430: 5 0 -AA-CUUCUAGGAGAACC-CAACA-dTdT-3 0 . siRNAs were purchased from Dharmacon and transfected using Lipofectamine-2000 (Invitrogen, Carlsbad, CA, USA) at the following concentrations: 800 ng siRNA þ 4 ml LF2000 per 1 Â 10 5 cells/ml in a six-well plate format with a final volume of 2 ml. siRNA duplexes against Luciferase GL3 RNA (5 0 -AA-CTTACGCTGAGTACTTC-GA-dTdT-3 0 ) or an FITC-conjugated siRNA from Dharmacon were used as controls.
Western blot analysis
Western blot analyses were performed as previously described (Deveraux et al., 1997) . Proteins were detected with the following primary antibodies: mouse anti-UbcH10 (1 : 1000), mouse anti-cyclin B (1 : 1000) (MBL International Corporation, Watertown, MA, USA), rabbit anti-caspase-3 (1 : 1000), mouse anti-caspase-7 (1 : 1000) (Pharmingen Incorporated, San Diego, CA, USA) and goat anti-actin polyclonal antibody (1 : 200) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), peroxidase-conjugated affinitypurified secondary antibodies (1 : 5000) (Bio-Rad, Hercules, CA, USA) and chemiluminescence (ECL; Amersham, Piscataway, NJ, USA).
Immunohistochemistry
Immunohistochemistry was performed as previously described (Welsh et al., 2003) .
Cell viability, caspase activation and phase-contrast photography
Cell viability was determined in two ways. For testing the effects of multiple siRNAs directed against the UbcH10 mRNA in tumor and normal cells, the MTT assay (Promega, Madison, WI, USA) was used to determine the relative number of viable cells in six-well plates seeded at 100 000 cells/ml for the times indicated in the text and figure legends. To determine the viability of cells treated with siRNA and anti-DR5 agonistic antibodies (DR5-A), cells were plated in six-well dishes as above and allowed to attach overnight. Cells were transfected with siUbcH10 or control siRNA (FITC-conjugated siRNA; Dharmacon, Lafayette, CO, USA) using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA) for 48 h followed by the addition of DR5-A for 6 h. Experiments were performed in triplicate and cells were counted using an automated cell counter (Beckman Coulter, Fullerton, CA, USA). To assess caspase activation following DR5-A treatment, cells were grown and treated exactly as above. Cells were harvested by scraping at 4 h post DR5-A treatment, spun in a bench-top centrifuge and subjected to a fluorogenic caspase-3/7 DVED assay as described (Stennicke, 2000) . Photographs of phase-contrast microscopic images ( Â 20 magnification) were obtained 6 h following the addition of DR5-A.
